Sv2C Gene is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
| Gene Overview | |
|---|---|
| Gene Symbol | SV2C |
| Full Name | Synaptic Vesicle Glycoprotein 2C |
| Chromosomal Location | 5q13.2 |
| NCBI Gene ID | 22983 |
| OMIM | 610516 |
| Ensembl ID | ENSG00000170873 |
| UniProt ID | Q9H0Y9 |
| Encoded Protein | SV2C Protein |
| Gene Overview | |
|---|---|
| Gene Symbol | SV2C |
| Full Name | Synaptic Vesicle Glycoprotein 2C |
| Chromosomal Location | 5q13.2 |
| NCBI Gene ID | 22983 |
| OMIM | 610516 |
| Ensembl ID | ENSG00000170873 |
| UniProt ID | Q9H0Y9 |
| Encoded Protein | SV2C Protein |
The SV2C gene (Synaptic Vesicle Glycoprotein 2C) encodes a critical component of synaptic vesicles. This gene is part of the SV2 family (SV2A, SV2B, SV2C) that is essential for proper synaptic function and neurotransmitter release. SV2C is particularly notable for its expression in dopaminergic neurons and its association with Parkinson's disease.
The SV2C gene encodes Synaptic Vesicle Glycoprotein 2C, a member of the SV2 family of proteins that are essential components of synaptic vesicles. SV2C is one of three isoforms (SV2A, SV2B, SV2C) that function as transporters within the presynaptic vesicle membrane. The protein contains 12 transmembrane domains and is involved in the regulated exocytosis of neurotransmitters.
SV2C plays a critical role in synaptic vesicle cycling and neurotransmitter release. It is thought to function as a transporter for small molecules, although its precise substrate remains under investigation. The protein contributes to the maintenance of synaptic vesicle pools and the fidelity of neurotransmission.
In the brain, SV2C is expressed in various regions including the basal ganglia, cortex, hippocampus, and cerebellum. It shows particular enrichment in dopaminergic neurons of the substantia nigra and striatum, making it relevant to Parkinson's disease research.
SV2C has been implicated in several neurodegenerative diseases:
Parkinson's Disease (PD): SV2C genetic variants have been associated with PD risk in genome-wide association studies. The protein's expression in dopaminergic neurons and its role in synaptic vesicle function make it a candidate for PD pathogenesis. SV2C may influence dopamine release and neuronal vulnerability in the substantia nigra.
Alzheimer's Disease (AD): Altered SV2C expression has been reported in AD brain tissue. The protein may play a role in synaptic dysfunction, which is an early hallmark of AD pathophysiology.
Epilepsy: SV2C mutations have been linked to epilepsy phenotypes in animal models. The protein's role in synaptic vesicle release suggests it may contribute to hyperexcitability disorders.
Schizophrenia: Some studies have suggested associations between SV2C genetic variants and schizophrenia risk, although this remains controversial.
SV2C exhibits a distinct expression pattern in the brain:
The expression of SV2C is developmentally regulated, with higher levels observed in the adult brain compared to embryonic stages.
The study of Sv2C Gene has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
Sheng J, et al. (2014). "Association of SV2C gene variants with Parkinson's disease in Chinese population." Neurology. PMID:24759861.
Chang CL, et al. (2017). "SV2C expression is reduced in the substantia nigra of Parkinson's disease brains." Neurobiology of Disease. PMID:28254380.
Madeo M, et al. (2021). "SV2C modulates dopaminergic neuron function and vulnerability to neurotoxic insults." Cell Reports. PMID:34077721.
Mai JK, et al. (2019). "Synaptic vesicle glycoprotein 2C: Structure, function, and disease relevance." Journal of Neurochemistry. PMID:31190345.
Yao PJ, et al. (2018). "Altered SV2C expression in Alzheimer's disease brains." Acta Neuropathologica Communications. PMID:29321056.